Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

Home
/
update
/
details

Risk-Reducing Surgeries Improve Survival in BRCA-Mutation Carriers Diagnosed with Breast Cancer by Age 40

NextEdge Admin

14 Dec 2024

2 min 13 sec

PARP Inhibition,Breast Cancer,BRCA-positive

A global study led by Dr. Matteo Lambertini (University of Genoa) reveals significant survival benefits from risk-reducing surgeries in BRCA1/2 mutation carriers diagnosed with breast cancer at or before age 40. The findings, presented at the 2024 San Antonio Breast Cancer Symposium (SABCS), analyzed 5,290 patients from the international BRCA BCY Collaboration study.

Among participants, 3,888 underwent at least one procedure: 2,910 had a risk-reducing mastectomy (RRM), 2,782 had a risk-reducing salpingo-oophorectomy (RRSO), and 1,804 underwent both. Patients who opted for RRM saw a 35% lower risk of death and a 42% reduction in breast cancer recurrence or secondary malignancies. RRSO patients experienced a 42% lower mortality risk and a 32% reduction in recurrence or second cancers, with the most substantial survival advantage observed in those with triple-negative breast cancer.

Notably, the survival benefit of RRSO was more pronounced in BRCA1 carriers (56% lower mortality risk) compared to BRCA2 carriers (15% reduction). The study highlights the critical role of incorporating risk-reducing surgeries into management plans for BRCA-mutated early-onset breast cancer patients.

However, Dr. Lambertini stressed the importance of balancing these procedures' benefits against potential risks, including infertility and early menopause—key considerations for younger patients.

This research marks the first robust evidence of long-term survival benefits from these surgeries for this high-risk population, offering a foundation for future treatment decisions and counseling.